Skip to content
OpenCapital
Get started

AbbVie ABBV Vyalev — Net revenues

Other product segments

Skyrizi
$4.48B+30.9%
Rinvoq
$2.12B+23.3%
All other
$1.03B-18.2%
Botox Therapeutic
$1.01B+16.5%
Vraylar
$905M+18.3%
Venclexta
$770M+15.8%
Humira
$688M-38.6%
Botox Cosmetic
$668M+20.1%
Imbruvica
$556M-24.7%
Mavyret
$351M+14.7%
Ubrelvy
$339M+41.3%
Qulipta
$296M+53.4%
Other Aesthetics
$286M-9.2%
Linzess
$283M+91.2%
Juvederm Collection
$232M+0.4%
Elahere
$198M+10.6%
Other Neuroscience
$125M-19.4%
Epkinly
$83M+62.7%

Similar metrics at other companies

Gilead Sciences logo
GILDVeklury — Total revenues
$144M-52.3%
XER
XERSGvoke — Product revenue, net
$20.8M-0.2%
XER
XERSRecorlev — Product revenue, net
$49.77M+94.9%
Alpha Cognition logo
ACOGProduct Net — Revenue
$3.5M+910%
XER
XERSKeveyis — Product revenue, net
$11.89M+4.0%
Ardelyx logo
ARDXProduct sales, net — Total revenues
$93.37M+37.7%

Other financials

Income statement

See full
Revenue$15.0B+12.4%
Gross profit$10.8B+15.4%
Operating income$4.0B+6.9%
Net income$695.0M-46.0%
EPS (diluted)$0.39-45.8%

Balance sheet

See full
Cash & equivalents$9.4B+81.5%
Total debt$62.4B+1.8%
Total equity-$6.7B-569%
Total assets$136.46B+0.2%

Cash flow

See full
Operating cash flow$3.8B+134%
CapEx$265.0M+12.8%
Free cash flow$3.6B+155%

Valuation

See full
Market cap$465.2B+39.1%
P/E128×+39.1×
P/S7.4×+1.7×

Profitability

See full
Gross margin70.7%0.0pp
Operating margin24.4%—
Net margin5.8%-1.5pp
FCF margin31.8%+5.0pp

Returns & leverage

See full
Return on equity89%+32.7pp
Debt / equity46.6×+38.6×
Current ratio0.8×0.0×

Where this comes from

Reported directly by AbbVie in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: AbbVie’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about AbbVie's vyalev — net revenues.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AbbVie's vyalev — net revenues?
AbbVie (ABBV) reported vyalev — net revenues of $201M in Q1 2026.
How has AbbVie's vyalev — net revenues changed year-over-year?
AbbVie's vyalev — net revenues increased by 219.0% year-over-year, from $63M to $201M.
What is the long-term trend for AbbVie's vyalev — net revenues?
Over 2 years (2023 to 2025), AbbVie's vyalev — net revenues has grown at a 1167.5% compound annual growth rate (CAGR), from $3M to $482M.
What does vyalev — net revenues mean?
This metric represents the total gross sales of the Vyalev product line minus returns, allowances, and rebates. It serves as a key indicator of market adoption and commercial traction for this specific therapeutic asset within the company's neurology portfolio. Tracking this revenue stream helps investors assess the product's contribution to overall top-line growth and its trajectory in capturing market share.